How much funding has Envisia Therapeutics raised?

Envisia Therapeutics has raised $41.5M in total funding, most recently a extension round round.

Who are Envisia Therapeutics's investors?

Envisia Therapeutics's investors include Canaan Partners, Existing investors, New Enterprise Associates, Pappas Capital, Morningside Technology Ventures, Wakefield Group.

When was Envisia Therapeutics founded?

Envisia Therapeutics was founded in 2013.

Where is Envisia Therapeutics headquartered?

Envisia Therapeutics is headquartered in Research Triangle Park, North Carolina, United States.

What industry is Envisia Therapeutics in?

Envisia Therapeutics operates in Biotech, Healthcare.

How many employees does Envisia Therapeutics have?

Envisia Therapeutics has 11-50 employees.

Envisia Therapeutics

Acquired

Extended-release drug delivery for eye disease

Research Triangle Park, United States · Founded 2013 · $41.5M raised

Biotech

Healthcare

Headquarters: Research Triangle Park, North Carolina
Employees: 11–50
Founded: 2013
Business Model: B2B

Website: envisiatherapeutics.com
Total Funding: $41.5M
Last Round: $16.5M Extension RoundMar 2016
Rounds: 2

About

Envisia Therapeutics is a clinical-stage biotechnology company based in Morrisville (Research Triangle Park), North Carolina, focused on developing novel sustained-release drug delivery platforms for ophthalmic diseases. The company's lead product, ENV515, is an extended-release travoprost implant for the treatment of open-angle glaucoma and ocular hypertension. Envisia employs engineered nanoparticle technology for both front-of-eye and back-of-eye drug delivery applications, and debuted with a $25 million Series A financing in November 2013.

Summary

Envisia Therapeutics is a Biotech company based in Research Triangle Park, United States, founded in 2013. It has raised $41.5M in total across 2 rounds, most recently a $16.5M Extension Round round in Mar 2016. Investors include Canaan Partners, Existing investors and New Enterprise Associates.